Thalomid thalidomide: Phase II; marketed to treat cutaneous manifestations of erythema nodosum leprosum (ENL)

In an open label trial of 63 patients with androgen-independent prostate cancer, 200

Read the full 136 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE